Bio-Path (BPTH) Stock Price Down 7.1%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares traded down 7.1% during trading on Friday . The stock traded as low as $0.23 and last traded at $0.26. 2,230,890 shares were traded during trading, an increase of 454% from the average session volume of 402,428 shares. The stock had previously closed at $0.28.

Several research firms have recently weighed in on BPTH. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective (down from $4.50) on shares of Bio-Path in a research report on Monday, November 13th. lowered their price objective on Bio-Path from $4.50 to $1.50 and set a “buy” rating for the company in a research report on Wednesday, November 15th. Finally, ValuEngine lowered Bio-Path from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Bio-Path presently has an average rating of “Hold” and a consensus price target of $1.67.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.02) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). analysts expect that Bio-Path Holdings, Inc. will post -0.08 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in shares of Bio-Path by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares in the last quarter. Sabby Management LLC increased its position in Bio-Path by 73.2% in the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after buying an additional 503,488 shares in the last quarter. HighTower Advisors LLC increased its position in Bio-Path by 0.3% in the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Bio-Path by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares in the last quarter. 9.55% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/12/03/bio-path-bpth-stock-price-down-7-1.html.

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

What are top analysts saying about Bio-Path Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Path Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit